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Abstract  
 
Objective: Selective Estrogen Receptor Modulators (SERMs) reduce breast cancer risk by 38%. 
However, uptake is low and the reasons are not well understood. This study applied Protection Motivation 
Theory (PMT) to determine factors associated with intention to take SERMs. 
 
Methods: Women at increased risk of breast cancer (N=107), recruited from two familial cancer clinics 
in Australia, completed a questionnaire containing measures of PMT constructs. Hierarchical multiple 
linear regression analysis was used to analyze the data. 
 
Results: Forty-five percent of women said they would be likely or very likely to take SERMs in the 
future. PMT components accounted for 40% of variance in intention to take SERMs. Perceived 
vulnerability, severity and response efficacy appeared the most influential in women’s decisions to take or 
not take SERMs.  
 
Conclusion: Many women are interested in SERMs as a risk management option. Accurate risk 
estimation and an understanding of the benefits of SERMs are critical to women’s decision making.  
 
Practice Implications: Health professionals need to explore women’s perceptions of their risk and its 
consequences, as well as providing clear evidence-based information about the efficacy of SERMs. 
Exploring the source and strength of beliefs about SERMs may allow more effective, tailored counseling.  
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1. Introduction  
 
Breast cancer is the most frequently diagnosed cancer among women worldwide, with an estimated 1.38 
million cases diagnosed in 2008, which accounted for approximately 23% of all new cancer cases (1). A 
woman’s individual risk of developing breast cancer is dependent on specific factors, the most important 
of which are increasing age and family history (2). The average lifetime risk for an individual with two 
affected first-degree relatives is approximately 20%, compared to 13% for those with one affected first-
degree relative (3). Women who carry a germline mutation in the BRCA1 or BRCA2 breast cancer 
predisposition genes have even higher risks (average lifetime risk estimates of 65% and 45% respectively 
(4)), though these account for a small proportion of breast cancers. 
Risk management strategies for women with an elevated risk of breast cancer include risk-
reducing surgeries, namely risk-reducing mastectomy, risk-reducing pre-menopausal salpingo-
oophorectomy and risk-reducing medication using selective estrogen receptor modulators (SERMs)(5) or 
aromatase inhibitors (6). There is strong evidence that SERMs, such as tamoxifen and raloxifene, taken 
daily for five years reduce breast cancer risk by 38%(5). However, current uptake of these agents is very 
low, even in women at high familial-risk (7-11). Whilst it has been estimated that 15% of women in the 
United States between the ages of 35 and 79 could potentially benefit from tamoxifen (12), less than 0.2% 
of women in this age range are taking tamoxifen for the prevention of breast cancer (13). Similarly, a 
recent national cohort study in Australia (kConFab) revealed that fewer than 3% have used SERMs for 
prevention, and only 0.3% have done so while not enrolled in a clinical trial (12).  
Little is understood about the reasons for this less than anticipated uptake of SERMs. 
Negative attitudes towards, and inadequate explanation of SERMs by clinicians (10) may play a 
role, but patient factors are also likely to be important. Patients may feel concerned about potential 
side effects, which include menopausal symptoms (such as hot flushes), increased risk of thrombosis 
and endometrial cancer, and decrease in sexual desire and satisfaction (14-17). Understanding how 
women make decisions in this context can aid in informing decisions, both in clinical practice and health 
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policy, as well as contributing to the development of evidence-based decision aids to enable women to 
make truly informed choices concordant with their values.  
Expectancy-value models provide a useful framework for understanding self-protective health 
behavior. Commonly used expectancy-value models include the Health Belief Model (HBM; 18), the 
Theory of Planned Behavior (TPB; 19) and Protection Motivation Theory (PMT; 20, 21). Recent 
reviews (22, 23) have concluded that PMT is superior to other models  in explaining protective 
behaviors, because it is more comprehensive and coherent. Essentially,	PMT	proposes	that	
protection	behavior	is	motivated	by	two	parallel	streams:	threat	appraisal	and	coping	
appraisal.	Threat	appraisal	is	formed	by	summing	factors	increasing	the	likelihood	of	a	
protective	response	‐	perceived	vulnerability	to	and	severity	of	the	health	threat	(in	this	case,	
breast	cancer),	minus	those	factors	that	decrease	the	probability	of	a	protective	response	‐		
intrinsic	and	extrinsic	rewards	(in	this	case,	avoiding	the	side	effects	of	SERMs).	Coping	
appraisal	is	formed	by	summing	appraisals	of	self‐efficacy	(one’s	perceived	ability	to	actually	
carry	out	the	protective	behavior)	and	response	efficacy	(the	belief	that	the	protective	
behavior	will	work)	less	any	costs	(e.g.	monetary,	time,	personal)	associated	with	
undertaking	the	protective	behavior	(20).”  
PMT includes the important construct of self-efficacy (the belief that one is capable of 
performing a behavior), present in neither the HBM nor TPB. TPB measures perceived behavioral 
control, a similar construct, but this has received less meta-analytical support as a predictor of both 
intentions and behaviors than self-efficacy (24). PMT also includes components of threat perception 
(perceived severity and perceived susceptibility) (lacking in TPB) and perceived-efficacy of the 
adaptive health behavior and intention to perform a health behavior (response-efficacy and 
protection-motivation) (lacking in HBM). Further, the PMT posits clear relationships between its 
components, while the HBM is often criticized for being organized as a catalogue of variables 
contributing to a behavior; thus the model provides no detail regarding the relationships between 
its constructs (25). Thus the PMT was chosen to guide measure selection for the current study. To 
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our knowledge no study to date has utilized PMT, or any other theoretical models, to increase 
understanding of decision-making about SERMs.  
The amount of protection motivation elicited is a function of the threat and coping appraisal 
processes. Essential to PMT is the postulation that the incentive to protect oneself from danger is a 
positive linear function of severity, vulnerability, response efficacy and self- efficacy and a negative 
linear function of rewards and response costs (20).  
The present study aimed to test whether PMT factors are associated with intention to take SERMs in 
women who have a moderate to high risk of breast cancer (see Figure 1). Consistent with Roger’s (20) 
postulation of PMT, it was predicted that low rewards, high perceived vulnerability, high severity, high 
response efficacy, high self-efficacy and low response costs would be associated with intention to take 
SERMs. Further, in accordance with previous meta-analyses (26, 27) of PMT assessing health-related 
intentions, it was predicted that coping appraisal would be more strongly associated with intention than 
threat appraisal. 
 
2. Methods 
 
2.1 Participants 
Participants were recruited from two Familial Cancer Clinics in Australia. Eligibility criteria included that 
participants be: considered by their Familial Cancer Centre clinician to be at moderate or high risk of 
breast cancer, competent in English, between the ages of 18 and 70 and unaffected with breast or ovarian 
cancer. Women who had undergone bilateral mastectomy or tested negative for a documented BRCA1 or 
BRCA2 family mutation were excluded. Participants who had previously undergone a risk-reducing 
oophorectomy were not excluded, as their remaining risk still made SERMs a viable option. Clinician 
estimates of risk were based on family history and BRCA1 and BRCA2 mutation status, using the 
definition formulated by The Australian National Breast and Ovarian Cancer Centre: high risk is greater 
than three times the population risk and moderate risk is one and a half to three times population risk (28).  
Page 6 of 27
Ac
ce
pte
d M
an
us
cri
pt
 
6 
 
 
2.2 Procedure 
Consecutive potentially eligible women were identified by each participating clinic from breast 
cancer risk assessment and high risk clinics. Clinicians sent women a letter advising them about the study 
with a ‘permission to contact’ form and a stamped, addressed return envelope. Women who gave 
permission were phoned by a researcher. Consenting women completed a web-based consent form and 
questionnaire. Those who preferred not to complete the questionnaire online, were mailed a paper-based 
questionnaire and consent form, with a stamped and addressed return envelope enclosed.  
 
2.3 Materials 
A fact sheet that provided information on SERMs, risk-reducing mastectomy and risk-reducing 
salpingo oophorectomy was provided to ensure all participants had at least a basic level of knowledge 
about risk-reducing options.  
 
2.4 Measures 
2.4.1 Demographic characteristics. 
 Variables assessed included: age, ethnicity, relationship status, menopausal status, BRCA1 or BRCA2 
mutation status, and whether and how much the participant currently smoked cigarettes. Also included 
were: parity; if the woman had children whether they were daughters; plans to have children in the 
future; a history of thrombosis; a family and/or personal history of uptake of risk-reducing mastectomy 
and/or oophorectomy and/or SERMs. 
 
2.4.2 Protection Outcome 
 The primary Protection Motivation outcome was assessed by a single item measuring intention to 
undergo SERMs treatment on a 5-point Likert-type scale anchored by very unlikely (1) to very likely (5).  
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2.4.3 PMT Variables 
PMT Variables were assessed using measures adapted from other scales (29) or informed by the literature 
on protection motivation in the cancer setting (30-32), as a literature review did not reveal any measures 
specifically developed for this population.  
Severity. Nine items assessed perceived seriousness of breast cancer. The Breast Cancer Fear Scale 
comprised eight of these items and has demonstrated high internal consistency (α=.91)(29). The 
remaining item explicitly asked whether having breast cancer would be serious. 
Vulnerability. One item assessed vulnerability using a Visual Analogue Scale (VAS) asking women to 
rate their chance of developing cancer on a scale of 0% (none) to 100% (inevitable). VASs are a 
common measure for assessing risk within the cancer setting (33).  
Rewards. Three items informed by the literature (e.g. 30, 32) assessed beliefs about the benefits of not 
engaging in the protective behavior of taking SERMs (e.g. I will not be prompted to think about cancer 
all the time).  
Response-costs. Ten items informed by the literature (e.g. 30, 32) assessed beliefs about the potential 
negative consequences of taking SERMs (e.g. inducing menopausal symptoms).  
Response-efficacy. Four items informed by qualitative findings (30) assessed women’s beliefs about the 
advantages of taking SERMs (e.g. to reduce distress or worry about developing breast cancer).  
Self-efficacy. Five items informed by the literature (e.g 31) assessed women’s beliefs about their ability 
to take SERMs in the face of specific obstacles (e.g. if my family did not want me to). 
All scales except vulnerability were responded to on 5-point Likert scales anchored by the labels: 
strongly disagree (1) and strongly agree (5). Composite subscale scores for threat and coping 
appraisal were generated as the sum of item scores, with higher scores indicating higher levels of the 
corresponding construct.  
 
2.5 Data Analysis 
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All analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 
17.  Multiple linear regression analysis was used to assess predictors of intention to take SERMs. Potential 
covariates were assessed by computing Pearson correlations with intention to take SERMs.  Variables were 
included in regression models if they were significantly correlated at the 0.25 level and/or had strong 
theoretical rationale, that is, were considered to have a meaningful relationship with the dependent variable 
in accordance with the recommendations of Hosmer and Lemeshow (34). The control variables, age, risk 
status, having children, intention to have a mastectomy and intention to have an oophorectomy, were 
entered in model 1.  All PMT variables were then entered into model 2. 
To test the hypothesis whether coping appraisal would be more strongly associated with intention 
than threat appraisal, multiple linear regression was again used. Scores for severity, response-efficacy and 
self-efficacy variables were each standardized to scales ranging from zero to one hundred in line with the 
VAS measuring vulnerability, in order to increase comparability. Threat-appraisal was then computed by 
summing the severity and vulnerability scores, while coping-appraisal was generated by summing response-
efficacy and self-efficacy scores for each participant.  Both threat appraisal and coping appraisal were 
mean-centered. After entering covariates into model 1 of the regression analysis, threat appraisal and 
coping appraisal were entered into model 2 and 3 respectively in order to compare whether threat or coping 
appraisal accounted for more variance in intention to take SERMs.  
 
3. Results 
3.1 Sample 
Of the 407 invitations mailed out, two were returned to sender and 117 women gave consent to 
complete this study. Of these, two women did not fit the eligibility criteria and were not invited to 
complete the questionnaire. One hundred and seven women completed the questionnaire and are included 
in the present analysis, representing a response rate of 26%. Analysis of de-identified data on non-
responders indicated that 53% of invited women at moderate risk participated in this study compared to 
33% and 24% of invited women at high risk and women with a BRCA1 or BRCA2 mutation respectively. 
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Pearson chi-square analysis revealed significant differences between the response rates of women at 
moderate risk and  women with a BRCA1 or BRCA2 mutation χ2(1, N =376) = 8.14, p = .01. 
The demographic and clinical characteristics of participants are summarized in Table 1. The mean 
age for all participants was 43 (SD=10.8). The final sample included those who were BRCA1 or BRCA2 
mutation positive (n=41), at high risk due to their family history but without a documented mutation 
(n=56) and at moderate risk due to their family history (n=10). Seventeen percent of women reported 
previously taking SERMs and 38% of women had a family member who has previously used SERMs, 
although the latter likely predominantly took SERMs after a diagnosis of breast cancer. 
 
3.2 Intention to take SERMs 
Forty-five percent of women indicated they would be likely or very likely to take SERMs in the 
future.  Correlation analysis was conducted to assess relationships between the dependent variable and 
potential covariates (see Table 2). Although age did not demonstrate a significant correlation with intention, 
an a priori decision was made to include both age and risk status as covariates in all multiple linear 
regressions due to strong theoretical rationale (35, 36). Intention to have a mastectomy and intention to 
have (or having had) an oophorectomy were included as binary covariates in all regressions, as research 
suggests women do not consider SERMs in isolation but rather as an addition or alternative to other such 
measures of risk reduction (37).  
History of blood clots and whether or not one smoked were investigated through correlation analysis 
with the dependent variable, however, no significant relationships were found and thus were not included as 
covariates.       
                                                                                                                                                                                
A multiple linear regression was conducted to assess the predictors of intention to take SERMs. 
Analysis indicated that the overall regression was significant, p<.001, and accounted for 52.2% of the total 
variance in intention (Table 3). Model 1 accounted for a significant proportion of the variance (R2=.12, p 
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=.04). Model 2 accounted for an additional 40% of the variance, p<.001 (Table 3). The PMT components of 
vulnerability (regression coefficient B=.01, p<.01), severity (B=.03, p<.01) and response efficacy (B=.23, 
p<.001) each made a significant unique contribution to the amount of variance explained.  
 
A second multiple linear regression was conducted to assess the effects of threat appraisal and 
coping appraisal on intention. Analysis indicated the overall regression model accounted for 44% of the 
total variance in intention (see Table 4). The addition of the threat-appraisal variable in model 2 explained 
an additional 9% of variance in intention over and above those variables in model 1 (R2=.09, p<.01). The 
addition of coping appraisal in model 3 explained an additional 23% of variance in intention (R2=.23, 
p<.001), hence in accordance with prediction, it appears that coping-appraisal is more strongly associated 
with intention than threat-appraisal.  
Sensitivity-analysis excluding women who had previously taken SERMs was conducted for all 
analyses and revealed very similar results.  
 
4. Discussion and Conclusion 
4.1 Discussion 
The present study was the first to our knowledge to apply any psychological theory in order to 
elucidate how women at increased risk of breast cancer make decisions regarding medical prevention using 
SERMs. Forty-five percent of women in the present study reported that they would be likely or very likely 
to take SERMs in the future. Whilst this is substantially greater than the reported uptake of 
chemoprevention, previous studies assessing intentions to take SERMs have ranged from 23% (38) to 62% 
(39). The intention-behavior ‘gap’, which has been well-documented in the health literature, may account 
for the discrepancy between studies assessing intentions and actual uptake of SERMs (40). It was not 
feasible, however, to assess future behavior in the current analysis. 
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 PMT was found to be a useful theoretical framework for understanding women’s intentions to take 
SERMs, with components of PMT explaining 40% of the variance in intention over and above the 
controlled-for variables. This amount of variance explained is comparable to that reported for breast cancer 
screening (39%)(22) but considerably greater than that reported for intention to perform breast self-
examination, where it explained only 25% (41) and 20% (42) of the variance.  
In accordance with prediction, high levels of severity, vulnerability and response-efficacy were all 
associated with greater intention to take SERMs. Thus if women believe that breast cancer has severe 
consequences, that they are at high risk of developing breast cancer and that SERMs are effective in 
reducing risk, they are more likely to intend to take up SERMs. Perceived risk has previously been found to 
be predictive of both considering taking tamoxifen (38) and uptake of tamoxifen (32). Notably, it is a well-
documented phenomenon that women overestimate their risk of breast cancer (35, 39, 43-45) and that 
perception of risk is rarely a direct comprehension of accurately understood probability information (32, 
46). Thus in medical consultations, particularly of women at moderate risk, health professionals need to 
carefully assess and discuss subjective risk.  
In accordance with our hypothesis, and congruent with meta-analyses of PMT (26, 27), coping-
appraisal appeared to be a stronger predictor of intention than threat-appraisal. Thus, the present study adds 
further support to the growing body of evidence suggesting that self-efficacy and response-efficacy should 
be included in social-cognition models of health (25).  More specifically, our results suggest that women’s 
individual beliefs about the efficacy of SERMs are extremely important. Thus, accurate and evidence-based 
information about SERMs efficacy is critical for women deciding between risk management options. Both 
clinicians’ and women’s preconceptions about the efficacy of SERMs need to be addressed. 
Notably, while women receive information about the efficacy of SERMs from clinicians, their 
beliefs may be influenced by other factors. For example, if a relative has taken SERMs but nonetheless 
developed breast cancer or had a recurrence, unaffected women are likely to develop negative views on 
SERMs efficacy. Thus it may be important in clinical practice to explore the source and strength of 
women’s beliefs about SERMs, and discuss how these factors may be influencing their decisions.  
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Our results are partially consistent with meta-analytic findings of studies using PMT to predict 
cancer-related preventive behavior, where vulnerability and response efficacy consistently emerge as key 
predictors (26, 47). Notably, while self-efficacy has emerged in the literature as the strongest predictor of 
intention (26, 27) it was not predictive of intention to take SERMs in the present study. One possible 
explanation for this inconsistency may be due to the nature of the protective behavior in this study. That is, 
few people would believe that they did not have the confidence to take a tablet a day. 
PMT would predict that intention is a negative linear function of the response costs associated with 
taking SERMs (such as side effects) and reinforcements or rewards associated with not taking SERMs 
(such as relief from constant reminders of cancer risk). However, surprisingly neither rewards nor response-
costs accounted for a significant amount of variance in intention to take SERMs.  This suggests, that either 
women do not put great weight on the side effects of SERMs or the opportunity to avoid cancer reminders 
in deciding whether or not to take SERMs, or that the measures used in the current study did not adequately 
assess these dimensions. The present study is only the third study predicting intention to undertake a health 
behavior (after Abraham et al. (48) and Helmes (49)) to include the rewards component. More research is 
needed to evaluate the complete PMT model. Until then, it is premature to conclude that side effects and the 
rewards associated with not taking SERMs, do not affect women’s decision-making.  
The present study has sampling and methodological limitations that warrant consideration. Previous 
research has demonstrated that women attending familial cancer clinics have above-average educational 
and socioeconomic levels suggesting that these women may not be representative of the broader population 
of women at increased risk of developing hereditary breast cancer (50-53). Nonetheless, our findings are 
highly relevant to countries such as Australia, where most assessment, genetic-testing and risk management 
of women at increased familial risk is done through Family Cancer Centers (10).  
Further, our participants reported a higher prevalence of previous use of SERMs than would be 
expected from the previous literature. This may have been because we excluded women who had opted for 
surgical procedures, or because we recruited from clinics with positive attitudes to SERMs, or because 
SERMs users were more likely to be interested in the study. Women who take SERMs may be highly 
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motivated and proactive about reducing their risk of breast cancer, and may not be representative of women 
at high risk of breast cancer in the general population. However, in sensitivity analyses excluding the 
women who had already taken SERMs, the results looked very similar, suggesting that at least for the 
measured variables, previous SERMs use did not change the pattern of women’s thinking about the 
decision to take SERMs.   
We were only able to recruit ten women at moderate risk of breast cancer, partially as a function of 
our method of recruitment, which was primarily through high risk clinics. Furthermore, women at moderate 
risk may have been reassured by the risk assessment provided at the clinic and may have therefore been less 
motivated to participate in the study. In addition, the present study had a relatively low response rate of 
26%. 
We included women who had had a risk-reducing oophorectomy, because such women can 
benefit from, and are offered SERMs in the clinic; however women who have chosen to have a 
prophylactic oophorectomy may differ from other high risk women. We did not have enough such 
women in the sample to explore systematic differences in this group.   
Another limitation of this study is that women are unlikely to consider SERMs in isolation but 
rather as an addition or alternative to other methods of risk reduction such as risk-reducing-mastectomy and 
risk-reducing-oophorectomy. However, it was not feasible in the current study to examine women’s 
preferences for multiple methods of risk reduction.  
Finally, due to the cross-sectional design of the present study, it is not known whether intention to 
take SERMs would necessarily translate into actual behavior. Future prospective cohort-studies are 
recommended.  
Despite these limitations, the present study has a number of strengths. The sample consisted of 
women from familial cancer centers who were all at increased risk of breast cancer and candidates for risk 
prevention using SERMs. These women were recruited from two centers, in different states. Further, the 
sample included women from the three risk groups (moderate, high and mutation positive) in order to 
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represent women from all risk groups eligible to take SERMs. Moreover, objective risk status was obtained 
from clinicians and included as a covariate in all analyses to assess the potential differences between these 
groups. 
 
4.2 Conclusion  
Protection motivation theory provided a useful framework with which to explore factors associated with 
women’s intentions to take SERMs. The degree to which a woman feels at risk of breast cancer, her 
perceptions of the seriousness of breast cancer and very importantly, her belief in the efficacy of SERMs, 
all contribute to her intention to take SERMs. Thus these issues require detailed discussion in the context of 
decision-making about risk reduction.   
 
4.3 Practice Implications 
The present findings have a number of implications for future research and clinical practice. Firstly, 
the results demonstrate that many women at increased risk of breast cancer are interested in using SERMs 
to reduce their risk.  
  The results suggest that to increase uptake of SERMs, health professionals should first focus on 
ensuring that women have accurate subjective risk perception and are informed about the proven long-term 
benefits of SERMs. It is important that clinicians not only provide women with information about the 
effectiveness of SERMs but also highlight the high quality of the studies from which this evidence was 
obtained. An effective way for this information to be conveyed would be through genetic counseling or 
evidence-based decision-aids. As individual preferences and issues vary, a tailored approach to 
chemoprevention counseling may be of particular benefit. 
Future research should assess women’s preferences for SERMs in the context of multiple options 
including risk-reducing-mastectomy and risk-reducing-oophorectomy. Such research would be particularly 
valuable as women do not consider SERMs in isolation. These studies should consider also recruiting 
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through primary-care physicians in order to ensure adequate representation of women at moderate as well 
as high risk of breast cancer.  
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Figure legends 
 
Figure 1. A schema outlining the cognitive mediating processes of protection motivation theory. 
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Figure 1. A schema outlining the cognitive mediating processes of protection motivation theory 
 
Page 24 of 27
Ac
ce
pte
d M
an
us
cri
pt
 
1 
 
Table 1. 
 
Demographic and clinical characteristics of participants at moderate risk of breast cancer, high 
risk of breast cancer and those with a mutation in the BRCA1 or BRCA2 gene. 
 
 
 
 
 
 
Variable 
 
Moderate Risk 
n=10 
High Risk 
n=56 
Mutation Positive 
n=41 
Combined 
 N=107 
M SD M SD M SD M SD 
Age  (years)  41.8 10.2 44.5 11.0 41.2 10.7 43.0 10.8 
 n % n % n % n % 
Ethnicity         
     Caucasian 7 70 51 91 34 83 92 86 
     Asian 
     Other 
0 
3 
0 
30 
2 
3 
4 
5 
2 
5 
5 
12 
4 
11 
4 
10 
Relationship Status         
    Single 1 10 10 18 8 20 19 18 
    Married/de facto 9 90 40 71 27 66 76 71 
    Widowed 0 0 2 4 0 0 2 2 
    Divorced 0 0 4 7 6 15 10 9 
Children         
    Yes  5 50 45 80 16 39 32 30 
    No 5 50 11 20 25 61 75 70 
Daughter/s         
     Yes 4 40 36 64 21 51 61 57 
     No 6 60 19 34 20 49 45 42 
Want future children         
     Yes 4 40 10 18 8 20 22 21 
     No 4 40 40 71 28 68 72 67 
     Unsure 1 10 6 11 5 12 12 11 
Menopausal status         
     Premenopausal 7 70 31 55 19 46 57 53 
     Perimenopausal 1 10 6 11 0 0 7 7 
    Post Menopausal 1 10 15 27 20 49 36 34 
     Unsure 1 10 4 7 2 5 7 7 
Family history of risk reducing mastectomy         
     Yes 3 30 14 25 17 41 34 32 
     No 7 70 42 75 24 59 73 68 
Family history of risk reducing oophorectomy         
      Yes 1 10 10 18 19 46 30 28 
     No 9 90 46 82 22 54 77 72 
Family history of SERMs         
     Yes 5 56 26 46 10 24 41 38 
     No 4 44 30 54 30 73 64 60 
Personal history of oophorectomy         
     Yes 0 0 8 14 19 46 27 25 
     No 10 100 48 86 22 54 80 75 
Personal history of SERMs         
      Yes 1 10 12 21 5 12 18 17 
      No 9 90 44 79 36 88 89 83 
Cigarettes per day         
     None 8 80 53 95 40 98 101 94 
     10 or less 2 20 3 5 0 0 5 5 
     11 to 20 0 0 0 0 1 2 1 1 
History of blood clots         
      Yes  1 10 0 0 0 0 1 1 
      No 9 90 56 100 41 100 106 99 
Table
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Table 2. 
 
Pearson correlation coefficients for potential covariates and dependent variables for adjusted 
analyses. 
 
 
Variable Intention 
(N =107 ) 
P value 
Age -0.06 .566 
Have children 0.19 .048 
Have daughter/s 0.20 .042 
Intention to have mastectomy  0.08 .444 
Intention to have oophorectomy 0.21 .033 
Perceived risk 0.30 .002 
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Table 3 
 
Multiple linear regression analysis predicting intention to take SERMs. Regression coefficients B and 95% confidence intervals (CI) are 
shown. 
 
Explanatory Variables  B (95% CI) p  Independent Variables B (95% CI) p 
Model 1 ( R2  = .12, ∆R2 =.12) 
 
 Age 
Risk status 
     Moderate 
     High 
     Mutation positive 
Has children 
Intention to have mastectomy 
Intention to have oophorectomy    
 
 
 
-.02 (-.04, .08) 
 
Reference 
.49 (-.41, 1.39) 
-.02 (-.99, .94) 
.51 (.08, 1.10) 
-.01 (-.53, .55) 
.63 (-.08,1.17)  
.04 
 
.16 
 
 
.28 
.96 
.09 
.98 
.02 
Model 2  ( R2  = .52, ∆R2 =.40) 
 
Age 
Risk status 
     Moderate 
    High 
     Mutation positive 
Has children 
Intention to have mastectomy 
Intention to have oophorectomy  
Rewards 
Vulnerability  
Severity 
Response Efficacy 
Self-efficacy 
Response Costs 
 
 
-.02 (-.04,.003) 
 
Reference 
-.11 (-.51, .58) 
-.16 (-1.06, .90) 
.46 (.62, .94) 
-.12 (-.55, .30) 
.28 (-.15, .71) 
-.02 (-.09, .05) 
.01 (.01, .02) 
.03 (.003, .06) 
.23 (.15, .31) 
.04 (-.01, .09) 
-.03 (-.07, .02) 
<.001 
 
.10 
 
 
.58 
.68 
.05 
.56 
.20 
.52 
.003 
.03 
<.001 
.11 
.27 
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Table 4 
 
Multiple linear regression analysis predicting intention to take SERMs. Regression coefficients B and 95% confidence intervals (CI) are 
shown. 
 
 Model 1 
(R2=.12, ∆ R2=.12)* 
 
 
Model 2 
( R2=.21, ∆ R2=.09)** 
 Model 3 
(R2=.44, ∆ R2=.23)** 
 
Explanatory Variables B (95%CI) p  B (95%CI) p  B (95%CI) p  
Age -.02 (-.04,.01) .16  -.01 (-.04, .01) .39  -.01 (-.03, .01) .24  
Risk Status          
     Moderate Reference   Reference   Reference   
     High .49 (-.41, 1.39) .28  .61 (-.25, 1.47) .17  .24 (-.50, .98) .52  
     Mutation positive -.02 (-.99, .94) .96  -.06 (-.86, .98) .90  .08 (-.71, .86) .85  
Has children .51 (-.08, 1.10) .09  .45 (.11, 1.01) .11  .42 (-.06, .89) .09  
Intention to have  mastectomy -.01 (-.53, .55) .98  -.15 (-.67, .37) .56  -.09 (-.53, .35) .68  
Intention to have oophorectomy    .63 (-.84, 1.17) .02  .61 (0.9, 1.13) .02  .39 (-.06, .83) .09  
Threat Appraisal    .01 (.01, .02) .001  .01 (.01, .02) .001  
Coping Appraisal       .02 (.02, .03) <.001  
* = Significant at the 0.05 level 
**= Significant at the 0.01 level 
 
 
 
